Cytokine Hemoadsorption in ECMO Patients

University Medical Centre Ljubljana

Status: Completed

Conditions: SIRS; Cytokine Storm; ARDS, Human; Cardiogenic Shock; Cardiac Arrest; Septic Shock

Study type: Observational

Funder types: Other

Identifiers

NCT04901338

Haemoadsorption ECMO

Details and patient eligibility

About

Cytokine hemoadsorption is a novel therapy used to improve outcome in critically ill patients with a dysregulated cytokine response and hemodynamic instability. Patients on extracorporeal membraneous oxygenation (ECMO) often develop severe systemic inflammatory response syndrome (SIRS). Cytokine removal using different types of hemoadsorption devices is believed to block the vicious circle of inflammation dysregulation when other basic therapeutic measures fail. To date there are very limited reports on ECMO and cytokine hemoadsorption combination therapy. The aim of this retrospective study is to evaluate feasibility and effectiveness of hemoadsorption in veno-arterial and veno-venous ECMO patients.

Enrollment: 25 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• VA/VV ECMO
• hemoadsorption
• Age ≥ 18 years

Exclusion criteria

• no additional exclusion criteria after being eligible for ECMO

Trial design

25 participants in 2 patient groups

Veno-arterial ECMO patients

Description:

Patients with severe SIRS post extracorporeal cardiopulmonary resuscitation (ECPR) or accompanying cardiogenic shock who were treated with hemoadsorption.

Veno-venous ECMO patients

Description:

Patients with refractory septic shock on VV ECMO who were treated with hemoadsorption.